Literature DB >> 26089069

Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis.

Julien Haroche1, Fleur Cohen-Aubart2, Jean-François Emile3, Jean Donadieu4, Zahir Amoura2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26089069     DOI： 10.1016/j.jaad.2014.10.045

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  5 in total

1.  Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis.

Authors:  Arno Dimmler; Helene Geddert; Martin Werner; Gerhard Faller
Journal:  Virchows Arch       Date:  2017-02-20       Impact factor: 4.064

2.  Cutaneous Langerhans cell histiocytosis : The spectrum of a rare cutaneous neoplasia.

Authors:  Uwe Wollina; Dana Langner; Gesina Hansel; Jacqueline Schönlebe
Journal:  Wien Med Wochenschr       Date:  2016-07-05

3.  Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.

Authors:  Dmitry Evseev; Irina Kalinina; Elena Raykina; Daria Osipova; Zalina Abashidze; Anna Ignatova; Anna Mitrofanova; Alexey Maschan; Galina Novichkova; Michael Maschan
Journal:  Int J Hematol       Date:  2021-08-12       Impact factor: 2.490

Review 4.  Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.

Authors:  Caroline Hutter; Milen Minkov
Journal:  Immunotargets Ther       Date:  2016-10-12

Review 5.  Bone metabolism in Langerhans cell histiocytosis.

Authors:  Athanasios D Anastasilakis; Marina Tsoli; Gregory Kaltsas; Polyzois Makras
Journal:  Endocr Connect       Date:  2018-07-02       Impact factor: 3.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.